Fundraising FoxChiesi Ventures — 2016 Investments
1 investments dated 2016 · listed companies and verified rows first · show all
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Board seatGiacomo Chiesi· per SEC Form D
Co-investorsAdvent Life SciencesAsahi Kasei Corporate Venture CapitalCTI Life Sciences Fund L.P.Mission Bay CapitalMission BiocapitalRemiges Ventures, Inc.+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.